Projects per year
Fingerprint Dive into the research topics where Mei-Jung Lai is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 13 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 4 Finished
組蛋白去乙醯酶在血管認知功能損傷中的作用-組蛋白去乙醯酶調節者在血管認知損傷動物可作為新的治療
1/1/19 → 12/1/19
Project: A - Government Institution › d - Ministry of Education
Design and Synthesis of Biaryl and Biphenylamino Sulfonamides as Novel Anticancer Agents
8/1/16 → 7/31/17
Project: A - Government Institution › b - Ministry of Science and Technology
設計與合成新穎苯甲醯胺與醯基羥胺取代之雜環化合物分別抑制微小管與組織蛋白去乙醯酉每6為抗癌藥物
11/1/14 → 10/31/15
Project: A - Government Institution › b - Ministry of Science and Technology
TMU103-AE1-B09
11/1/14 → 10/31/16
Project: B - Project of TMU › g - Research Grants for Newly Hired Faculty
Research Output
Corrigendum to “1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma” [Eur. J. Med. Chem. 140 (2017) 84–91](S0223523417306931)(10.1016/j.ejmech.2017.09.011)
Liu, Y. M., HuangFu, W. C., Huang, H. L., Wu, W. C., Chen, Y. L., Yen, Y., Huang, H. L., Nien, C. Y., Lai, M. J., Pan, S. L. & Liou, J. P., Sep 15 2020, In : European Journal of Medicinal Chemistry. 202, 112633.Research output: Contribution to journal › Comment/debate
Open Access
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Jun 15 2020, In : European Journal of Medicinal Chemistry. 196, 112329.Research output: Contribution to journal › Comment/debate
Open Access
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., Sep 1 2020, In : European Journal of Medicinal Chemistry. 201, 112404.Research output: Contribution to journal › Comment/debate
Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Apr 15 2020, In : European Journal of Medicinal Chemistry. 192, p. 112158 112158.Research output: Contribution to journal › Article
Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells
Wu, W. C., Liu, Y. M., Liao, Y. H., Hsu, K. C., Lien, S. T., Chen, I. C., Lai, M. J., Li, Y. H., Pan, S. L., Chen, M. C. & Liou, J. P., Oct 1 2020, In : European Journal of Medicinal Chemistry. 203, 112540.Research output: Contribution to journal › Article